Table 2.
Input and output values for each country selected
| Country | Vietnam [16] | Egypt [17] | Philippines [18] | Algeria [19] | Turkey [20] | Portugal [21] | France [15] | The Netherlands [22] | Norway [23] |
|---|---|---|---|---|---|---|---|---|---|
| Birth cohort | 1,639,000 | 1,909,000 | 2,266,887 | 621,790 | 1,257,583 | 109,457 | 750,000 | 187,910 | 60,000 |
| Life expectancy (years) [24] | 71.6 | 68.0 | 66.6 | 74.3 | 73.3 | 76.6 | 77.5 | 78.5 | 80 |
| Hospitalizations up to age 5 years | 32,331 | 53,342 | 17,448 | 11,000 | 36,797 | 1,200 | 17,932 | 2,940 | 905 |
| Hospital rate for the birth cohort | 1.97% | 2.79% | 0.77% | 1.77% | 2.93% | 1.10% | 2.39% | 1.56% | 1.51% |
| Hospital cost per event | $20 | $19 | $45 | $650 | $400 | $2,172 | $1,400 | $2,172 | $2,382 |
| Deaths up to age 5 years | 6,050 | 3,200 | 4,438 | 300 | 13 | 1 | 9 | 2 | 1 |
| Death rate | 0.37% | 0.17% | 0.20% | 0.048% | 0.0010% | 0.0009% | 0.0012% | 0.0011% | 0.0017% |
| GDP [5] | $3,359 | $6,455 | $4,080 | $7,325 | $14,393 | $23,363 | $35,068 | $42,023 | $53,396 |
| VE in the model | 64% | 64% | 64% | 64% | 87% | 90% | 90% | 90% | 90% |
| Pn (per dose) | $0.12 | $0.15 | $0.16 | $3.76 | $5.58 | $11.30 | $15.80 | $16.09 | $17.81 |
| Pm (per dose) | $111.26 | $145.61 | $101.29 | $52.61 | $7.61 | $14.04 | $20.53 | $20.13 | $28.56 |
| Price range (Pm–Pn) | $111.14 | $145.46 | $101.13 | $48.85 | $2.03 | $2.74 | $4.73 | $4.04 | $10.75 |
| CostDNV | $0.39 | $0.54 | $0.35 | $12.69 | $11.70 | $23.81 | $33.47 | $33.98 | $35.97 |
| CostDV | $0.14 | $0.23 | $0.03 | $5.18 | $0.54 | $1.22 | $1.87 | $1.80 | $0.38 |
| CostDNV − CostDv | −$0.25 | −$0.31 | −$0.32 | −$7.51 | −$11.16 | −$22.59 | −$31.60 | −$32.18 | −$35.59 |
| E NV | −0.105 | −0.0471 | −0.0560 | −0.014 | −0.000297 | −0.00025 | −0.000297 | −0.00022 | −0.00041 |
| E V | −0.039 | −0.0021 | −0.0064 | −0.0006 | −0.000014 | −0.00002 | −0.000027 | −0.000023 | −0.000004 |
| E NV − E V | 0.066 | 0.045 | 0.0496 | 0.0134 | 0.000283 | 0.00023 | 0.000270 | 0.000197 | 0.000406 |
| a | 15 | 22 | 20 | 75 | 3,534 | 4,348 | 3,704 | 5,076 | 2,463 |
| b | −4 | −7 | −6 | −560 | −39,431 | −98,217 | −117,037 | −163,350 | −87,660 |
a slope of the linear regression, b intercept, CostD NV initial disease-related cost in the absence of vaccination (no vaccine), CostD v remaining disease-related cost with vaccination, E NV health losses without vaccination (no vaccine), E V health losses after vaccination, GDP gross domestic product, Pm maximum price, Pn cost neutral price, VE vaccine efficacy